European Innovation Council

PrecisionLife is a company focused on advancing precision medicine by leveraging its proprietary artificial intelligence platform to enhance the understanding of chronic diseases. It specializes in patient stratification, which allows for the identification of novel subgroups within patient populations, thereby generating insights that inform the discovery of new drug targets and drug repositioning candidates. By utilizing unique and patentable biomarkers, PrecisionLife connects patients with specific disease sub-groups and potential therapies, ultimately aiming to create personalized treatment alternatives. The company’s innovative approach not only drives advancements in biopharmaceuticals but also seeks to improve patient outcomes, enabling individuals to lead longer and healthier lives.

Aplagon is a biopharmaceutical company focused on developing innovative antithrombotic medications aimed at addressing complications associated with vascular interventions, particularly blood vessel occlusions. The company specializes in creating biological mimetics of heparin proteoglycan, which are intended for the clinical management of thrombotic occlusions and ischemic reperfusion injuries. Aplagon's mission is to provide patients with effective treatment options that offer significant safety advantages, thereby fulfilling unmet medical needs in the field of vascular health.

Tensive is a biomedical startup established in 2012 to develop innovative prostheses aiming to offer a natural breast reconstruction or augmentation.Tensive is a biomedical startup established in 2012 to develop innovative prostheses aiming to offer a natural breast reconstruction or augmentation.

Acorai is developing a non-invasive heart failure monitoring platform centered on direct intracardiac pressure monitoring (ICPM). The company utilizes a patented combination of sensor technologies and machine learning to provide accurate and cost-efficient heart failure care. This innovative approach allows for non-invasive monitoring of cardiac and pulmonary pressure, which is crucial for improving outcomes in heart failure patients. By analyzing pressure dynamics through acoustic, vibratory, and waveform data, the device enables healthcare professionals to proactively adjust medications, potentially reducing re-hospitalization and mortality rates associated with heart failure. Clinically validated and designated as an FDA Breakthrough Device, Acorai's product is expected to enter the market in 2025.

MediWound Ltd. is a biopharmaceutical company that specializes in the development, manufacturing, and commercialization of innovative therapeutic products aimed at addressing unmet medical needs, particularly in the areas of severe burns and chronic wounds. Founded in 2000 and headquartered in Yavne, Israel, it markets NexoBrid, a biopharmaceutical agent designed for the removal of eschar, or dead tissue, in patients with severe burns. NexoBrid has completed clinical development and is approved for use in Europe. The company is also advancing other products in its pipeline, including EscharEx, which has completed Phase II clinical trials for the debridement of chronic wounds, and MWPC003 for connective tissue disorders. MediWound aims to improve patient outcomes and reduce the complications associated with traditional surgical interventions in wound management.

MediWound Ltd. is a biopharmaceutical company that specializes in the development, manufacturing, and commercialization of innovative therapeutic products aimed at addressing unmet medical needs, particularly in the areas of severe burns and chronic wounds. Founded in 2000 and headquartered in Yavne, Israel, it markets NexoBrid, a biopharmaceutical agent designed for the removal of eschar, or dead tissue, in patients with severe burns. NexoBrid has completed clinical development and is approved for use in Europe. The company is also advancing other products in its pipeline, including EscharEx, which has completed Phase II clinical trials for the debridement of chronic wounds, and MWPC003 for connective tissue disorders. MediWound aims to improve patient outcomes and reduce the complications associated with traditional surgical interventions in wound management.

Endoron Medical specializes in the development of medical devices aimed at improving the treatment of abdominal aortic aneurysms. The company focuses on creating an endovascular suture device that enhances the effectiveness of endovascular aneurysm repair procedures. By designing long-lasting sealing equipment for endografts, Endoron Medical provides healthcare professionals with advanced technology to treat patients more effectively. This innovation is intended to improve patient outcomes and streamline surgical processes in the management of abdominal aortic aneurysms.

UroMems is a company dedicated to addressing specific clinical needs related to patient care, particularly in the area of urology. It develops implantable medical devices aimed at enhancing existing surgical treatments, thereby improving patient outcomes and reducing side effects. By focusing on innovative solutions, UroMems seeks to ensure that more patients can access effective treatments quickly, ultimately aiming to enhance their quality of life. The company is committed to the design, development, and commercialization of these active implantable devices, which reflect a deep understanding of the challenges faced by patients.

iOnctura is a biopharmaceutical company that develops novel therapeutics aimed at addressing immunosuppression within the tumor microenvironment, which can hinder effective cancer treatment. The company focuses on creating next-generation biomolecules to enhance existing immune checkpoint therapies, ultimately aiming to improve patient outcomes in cancer treatment. Through collaborations with Merck and Cancer Research Technology, iOnctura is advancing a pipeline of preclinical molecules designed to be used in combination with immuno-oncology therapies. With access to state-of-the-art drug discovery laboratories and a network of academic partners, iOnctura is strategically positioned to develop innovative combination therapies in cancer immunology, ensuring a focused approach to tackling the complexities of cancer and fibrosis.

Palobiofarma is a Spanish biotechnology company based in Barcelona's Science Park, dedicated to the discovery and development of new drugs that target adenosine receptors. The company aims to be a leader in adenosine drug discovery in Europe by focusing on innovative therapies. Palobiofarma specializes in creating selective adenosine receptor modulators, with a particular emphasis on addressing advanced prostate cancer. By leveraging medicinal chemistry and in vitro pharmacology, the company is working towards bringing its first marketed drug to the medical community, supporting healthcare professionals in their efforts to treat this challenging disease.

Sentante is a medical device company focused on developing robotic teleoperated systems specifically for endovascular procedures. By utilizing this innovative technology, Sentante enables physicians to perform surgeries remotely, significantly reducing their exposure to harmful X-rays. The company has designed a manipulator that assists endovascular practitioners in conducting procedures with minimal radiation risk, promoting safer practices in the medical field. Additionally, Sentante's robotic systems facilitate minimally invasive coronary procedures, enhancing the ability of surgeons to carry out complex endovascular surgeries while also contributing to a decrease in oncological diseases among healthcare personnel.

NETRIS Pharma S.A.S. is a biotechnology company based in Lyon, France, that specializes in identifying and developing therapeutic molecules aimed at treating cancer. The company's innovative approach focuses on targeting dependence receptors, which are trans-membrane proteins that play a crucial role in signaling within cells and regulating tumor development. NETRIS Pharma offers both in vitro and in vivo research services, along with preclinical practices, to advance drug manufacturing for various types of cancer, including breast cancer, lung cancer, glioblastoma, and neuroblastoma. Founded in 2008, the company is dedicated to contributing to the pharmaceutical industry by developing novel cancer therapies.

Antabio is a private biopharmaceutical company based in Labege, France, focused on developing novel treatments for drug-resistant infections, particularly targeting critical priority pathogens. Founded in 2009, the company specializes in creating antibacterial resistance-breakers that can restore the efficacy of existing antibiotics. Its key innovation includes inhibitors of bacterial metalloenzymes, specifically Metallo ß-lactamases (MBLs), which are designed to be used in combination with carbapenems to address significant treatment gaps in drug-resistant nosocomial infections. Antabio aims to provide health professionals with effective medicinal products to combat life-threatening respiratory infections, including carbapenem-resistant pneumonia and chronic pulmonary diseases. The company has received recognition for its research efforts, including a Wellcome Trust Seeding Drug Discovery Award.

Methinks is a developer of a medical imaging platform that leverages advanced artificial intelligence techniques, including Google's TensorFlow, to enhance the diagnosis of brain-related diseases, particularly acute stroke. The platform facilitates timely and universal diagnosis by using non-contrast CT imaging, which eliminates the need for contrast CT scans and significantly reduces time-to-treatment. This capability enables radiologists to effectively communicate with hospitals, stroke units, and other healthcare professionals, thereby improving the overall clinical response to stroke cases. By focusing on specific pathologies, Methinks aims to achieve clinical excellence in the diagnosis and management of neurological conditions.

NEOGAP Therapeutics is a clinical-stage biopharmaceutical startup focused on immuno oncology. Their pharmaceutical product, personalized tumor trained lymphocytes, offers even one customized cell treatment that is meant to precisely target and destroy cancer in a tailored environment, with very minor side effects.

Acorai is developing a non-invasive heart failure monitoring platform centered on direct intracardiac pressure monitoring (ICPM). The company utilizes a patented combination of sensor technologies and machine learning to provide accurate and cost-efficient heart failure care. This innovative approach allows for non-invasive monitoring of cardiac and pulmonary pressure, which is crucial for improving outcomes in heart failure patients. By analyzing pressure dynamics through acoustic, vibratory, and waveform data, the device enables healthcare professionals to proactively adjust medications, potentially reducing re-hospitalization and mortality rates associated with heart failure. Clinically validated and designated as an FDA Breakthrough Device, Acorai's product is expected to enter the market in 2025.

SolasCure Limited is a biotechnology company based in Wales, United Kingdom, focused on developing innovative solutions for patients with chronic wounds. Founded in 2017, the company is advancing its product Aurase, a hydrogel designed to facilitate wound debridement by removing dead, damaged, or infected tissue to enhance healing. Aurase incorporates a recombinant enzyme derived from maggots, leveraging biomimicry and evidence-based medicine to improve wound care outcomes. SolasCure aims to provide effective wound bed preparation across various healthcare settings, ultimately accelerating the healing process for individuals suffering from chronic wounds.

Microsure is a medical device company based in Eindhoven, The Netherlands, founded in 2014. It specializes in developing innovative solutions for microsurgery, a field that operates at the limits of physical capabilities. The company's flagship product is a motion stabilizer system designed specifically for microsurgeons, which enhances surgical precision by filtering out tremors and providing exceptional control during procedures. This technology allows for hybrid microsurgical procedures that enable surgeons to utilize their own instruments, thereby reducing costs for hospitals. The Microsure motion stabilizer has demonstrated its effectiveness in clinical trials, including successful operations for lymphedema. By improving the quality of microsurgical procedures, the company aims to expand treatment options for patients and facilitate the development of new, highly accurate surgical techniques.

EyeControl is a pioneer in medical technology focused on innovative communication solutions for healthcare. The company has developed a unique device aimed at improving the quality of life for patients with locked-in syndrome, particularly those suffering from ALS. This device consists of a simple glass frame equipped with an infrared camera that connects to a compact computer. It translates the patients' blinks and eye movements into commands, which are then converted into speech through earphones and a speaker. By leveraging advanced technology, EyeControl addresses significant communication barriers, enabling patients to express their needs and preferences more effectively.

Diagnostic of preterm birth risk and induction labor success probabilities through the use of torsional ultrasound technology

Genomika Lietuva is a business that provides cutting-edge, perceptive, and meticulously optimized solutions for the biomedical sciences. It creates DNA storage technologies that allow for high-density storage of significant amounts of information in a remarkably tiny area.

Elgan Pharma is a biotechnology company specializing in neonatology, dedicated to addressing medical challenges and developmental issues faced by premature infants. The company is focused on developing innovative therapies utilizing nanotechnology to prevent visual impairment, a common and multifactorial problem in preterm babies. By targeting the specific needs of this vulnerable population, Elgan Pharma aims to enhance visual outcomes and reduce the risk of significant disabilities, ultimately supporting healthcare professionals in their efforts to improve the quality of life for these infants.

Cellbox Solutions is a young technology company that focuses on innovative logistic solutions for the global BioMed industry.

EBAMed SA is a Swiss startup based in Geneva, established in 2018, that focuses on developing innovative medical technology for treating heart arrhythmias. The company is working on an ultrasound-based device designed to monitor heart motion and facilitate non-invasive ablation therapy using proton beams. This technology aims to provide a safe and effective alternative for patients by allowing real-time synchronization of proton therapy with heart movement. By integrating both hardware and software components, EBAMed's device enhances treatment capabilities for existing proton therapy centers, enabling them to offer advanced, non-invasive treatment options for cardiac patients in an outpatient setting.

Escala Medical is focused on developing a minimally invasive medical device aimed at treating pelvic organ prolapse (POP) in women. The company's innovative system offers a nonsurgical, incision-free, and mesh-free repair option that addresses the vaginal apex by connecting it to the sacrospinous ligament. This approach is designed to be safe, quick, and to preserve organ functionality while minimizing patient discomfort. The procedure can be performed in outpatient and office-based settings, providing a much-needed alternative for women suffering from POP.

Escala Medical is focused on developing a minimally invasive medical device aimed at treating pelvic organ prolapse (POP) in women. The company's innovative system offers a nonsurgical, incision-free, and mesh-free repair option that addresses the vaginal apex by connecting it to the sacrospinous ligament. This approach is designed to be safe, quick, and to preserve organ functionality while minimizing patient discomfort. The procedure can be performed in outpatient and office-based settings, providing a much-needed alternative for women suffering from POP.

InProTher is an immunotherapy company dedicated to developing the world’s first adaptive immune therapy capable of targeting immunosuppressive genes of ancient retroviruses.

ReLink is an advanced breakaway connector for IV lines, designed to reduce complications and costs associated with accidental disconnection events in healthcare settings, a leading challenge in hospital and homecare infusions.

ARTHEx Biotech S.L. is a spin-off company of the University of Valencia that is developing antisense RNA treatments against genetic diseases. Our team has a strong background on drug discovery and microRNAs involvement in neuromuscular diseases. We are supported by world-renowned scientific and clinical advisors that will facilitate the successful development of our products.

3DSecret is developing cutting-edge technologies to uncover the stochastic patterns behind metastasis in order to predict the course of cancer.

Abbelight specializes in super-resolution microscopy and membrane imaging, focusing on single molecule localization microscopy to enhance biological research. The company integrates consumables, hardware, and software to deliver advanced scientific solutions, allowing researchers in biology, pharmacology, and environmental studies to utilize super-resolved fluorescence microscopy for improved observation of biological samples. Abbelight aims to democratize access to these sophisticated techniques by simplifying their application while maintaining high performance standards. To support scientists throughout the research process, Abbelight offers expertise in sample preparation and result analysis, providing a comprehensive approach that combines chemistry, computer science, and optical instruments.

Samplix is a biotechnology company based in Herlev, Denmark, focused on single-molecule sample preparation for DNA and RNA. It has developed the Xdrop™ technology, which utilizes a unique “water-oil-water” droplet system to create millions of reaction chambers for handling individual DNA molecules. This innovative approach allows for targeted enrichment of large DNA fragments and enables researchers to sequence specific genetic regions effectively. Samplix's technology addresses the limitations of existing multi-molecule preparation methods, providing enhanced precision and sensitivity while simplifying the sample preparation process. Its solutions empower scientists to make informed research decisions, particularly in applications related to virus integration and CRISPR editing.

Smart Immune is a clinical-stage biotechnology company focused on developing innovative hematopoietic stem cell-based therapies aimed at improving the prognosis and quality of life for patients with serious diseases. The company's primary program utilizes T cell progenitors, known as ProTcells, which are designed to facilitate a rapid and safe immune recovery following transplantation. This therapy seeks to provide a polyclonal immune response, enhancing the body's ability to combat cancers and infections. Additionally, Smart Immune plans to complement its core offerings with advancements in targeted conditioning, gene therapy, and genome editing, thereby creating next-generation treatments for a range of inherited blood disorders and hematological malignancies.

Samplix is a biotechnology company based in Herlev, Denmark, focused on single-molecule sample preparation for DNA and RNA. It has developed the Xdrop™ technology, which utilizes a unique “water-oil-water” droplet system to create millions of reaction chambers for handling individual DNA molecules. This innovative approach allows for targeted enrichment of large DNA fragments and enables researchers to sequence specific genetic regions effectively. Samplix's technology addresses the limitations of existing multi-molecule preparation methods, providing enhanced precision and sensitivity while simplifying the sample preparation process. Its solutions empower scientists to make informed research decisions, particularly in applications related to virus integration and CRISPR editing.

Smart Immune is a clinical-stage biotechnology company focused on developing innovative hematopoietic stem cell-based therapies aimed at improving the prognosis and quality of life for patients with serious diseases. The company's primary program utilizes T cell progenitors, known as ProTcells, which are designed to facilitate a rapid and safe immune recovery following transplantation. This therapy seeks to provide a polyclonal immune response, enhancing the body's ability to combat cancers and infections. Additionally, Smart Immune plans to complement its core offerings with advancements in targeted conditioning, gene therapy, and genome editing, thereby creating next-generation treatments for a range of inherited blood disorders and hematological malignancies.

Sensius B.V., founded in 2015 and based in Rotterdam, Netherlands, specializes in developing advanced thermotherapy systems for treating head and neck cancers. The company's proprietary technology incorporates localized heating through an integrated microwave system, complemented by interactive software, which allows healthcare professionals to enhance traditional cancer treatments such as radiotherapy and chemotherapy. This innovative approach aims to improve patient outcomes and quality of life by mitigating the toxic effects commonly associated with standard therapies. Sensius has successfully treated seventy patients with its device, achieving a complete response rate of 81.8% at 12 weeks post-treatment. Currently, the company is working towards obtaining CE marking for its device, with significant interest from potential buyers, as it also plans to expand its application to other cancer types in the future.

Sensius B.V., founded in 2015 and based in Rotterdam, Netherlands, specializes in developing advanced thermotherapy systems for treating head and neck cancers. The company's proprietary technology incorporates localized heating through an integrated microwave system, complemented by interactive software, which allows healthcare professionals to enhance traditional cancer treatments such as radiotherapy and chemotherapy. This innovative approach aims to improve patient outcomes and quality of life by mitigating the toxic effects commonly associated with standard therapies. Sensius has successfully treated seventy patients with its device, achieving a complete response rate of 81.8% at 12 weeks post-treatment. Currently, the company is working towards obtaining CE marking for its device, with significant interest from potential buyers, as it also plans to expand its application to other cancer types in the future.

TILT Biotherapeutics Ltd is a preclinical stage biotechnology company based in Helsinki, Finland, specializing in the development of genetically modified oncolytic viruses aimed at enhancing cancer treatments. The company's patented technology focuses on using these viruses to improve tumor T-cell therapies, including tumor-infiltrating lymphocyte (TIL) and chimeric antigen receptor (CAR-T) therapies, as well as checkpoint inhibitors. TILT Biotherapeutics is recognized as a leader in the global market for integrating oncolytic viruses with cancer immunotherapy. Their product pipeline includes TILT-123, TILT-234, and TILT-321, which are designed to modify the tumor microenvironment and counteract its suppression of immune responses. The innovative approach has the potential to replicate the successes seen in CAR-T therapy for solid tumors, similar to those achieved in hematological cancers.

TILT Biotherapeutics Ltd is a preclinical stage biotechnology company based in Helsinki, Finland, specializing in the development of genetically modified oncolytic viruses aimed at enhancing cancer treatments. The company's patented technology focuses on using these viruses to improve tumor T-cell therapies, including tumor-infiltrating lymphocyte (TIL) and chimeric antigen receptor (CAR-T) therapies, as well as checkpoint inhibitors. TILT Biotherapeutics is recognized as a leader in the global market for integrating oncolytic viruses with cancer immunotherapy. Their product pipeline includes TILT-123, TILT-234, and TILT-321, which are designed to modify the tumor microenvironment and counteract its suppression of immune responses. The innovative approach has the potential to replicate the successes seen in CAR-T therapy for solid tumors, similar to those achieved in hematological cancers.

Syntach is a medical device company focused on improving the care of individuals with heart failure through the development of a cardiac support device. This innovative device aims to restore the impaired movement of the mitral valve and provide natural support to the heart. Syntach offers a permanent, active implant that can be inserted using a minimally invasive technique, making it smaller than existing left ventricular assist devices (LVADs). This design not only enhances the quality of life for patients but also reduces the risk of complications, benefiting both men and women who require cardiac support.

iThera Medical specializes in advanced biomedical imaging technology, focusing on photonic molecular imaging. Founded in 2010 as a spin-off from the Helmholtz Zentrum Muenchen, the company collaborates with this research center to enhance its proprietary Multi-Spectral Optoacoustic Tomography (MSOT) technology. This innovative approach provides real-time visualization of anatomical, functional, and molecular information within living tissue, which aids in the detection of tumors and inflammatory diseases. By enabling non-invasive diagnostic capabilities, iThera Medical supports both preclinical and clinical applications, offering significant advancements in medical imaging and patient care.

Dxcover is a clinical-stage liquid biopsy company based in Glasgow, founded in 2016 by David S Palmer, Holly Butler, and Matthew Baker. The firm focuses on developing innovative diagnostics for the early detection of various cancers, which is crucial for improving treatment outcomes. Dxcover has pioneered the use of infrared spectroscopy combined with artificial intelligence to analyze circulating pan-omic indicators, allowing for the identification of cancer from a simple blood sample. This approach enables same-day diagnosis and patient stratification, facilitating timely interventions. The company has demonstrated strong clinical data supporting the accurate diagnosis of Stage I and Stage II cancers, underscoring its commitment to enhancing survival rates and quality of life for patients.

Sonio is an AI-based support platform for fetal ultrasound, helping practitioners analyze and diagnose congenital malformations. Sonio combines the patient’s medical history, genetic and biological data, and ultrasound semiology to assist physicians on the path to the right diagnosis. It assists sonographers during prenatal screening scans, helping them ensure that they have not forgotten anything, take risk factors into account, and facilitate the sharing of images with patients and other health professionals.

Sonio is an AI-based support platform for fetal ultrasound, helping practitioners analyze and diagnose congenital malformations. Sonio combines the patient’s medical history, genetic and biological data, and ultrasound semiology to assist physicians on the path to the right diagnosis. It assists sonographers during prenatal screening scans, helping them ensure that they have not forgotten anything, take risk factors into account, and facilitate the sharing of images with patients and other health professionals.

iOnctura is a biopharmaceutical company that develops novel therapeutics aimed at addressing immunosuppression within the tumor microenvironment, which can hinder effective cancer treatment. The company focuses on creating next-generation biomolecules to enhance existing immune checkpoint therapies, ultimately aiming to improve patient outcomes in cancer treatment. Through collaborations with Merck and Cancer Research Technology, iOnctura is advancing a pipeline of preclinical molecules designed to be used in combination with immuno-oncology therapies. With access to state-of-the-art drug discovery laboratories and a network of academic partners, iOnctura is strategically positioned to develop innovative combination therapies in cancer immunology, ensuring a focused approach to tackling the complexities of cancer and fibrosis.

iOnctura is a biopharmaceutical company that develops novel therapeutics aimed at addressing immunosuppression within the tumor microenvironment, which can hinder effective cancer treatment. The company focuses on creating next-generation biomolecules to enhance existing immune checkpoint therapies, ultimately aiming to improve patient outcomes in cancer treatment. Through collaborations with Merck and Cancer Research Technology, iOnctura is advancing a pipeline of preclinical molecules designed to be used in combination with immuno-oncology therapies. With access to state-of-the-art drug discovery laboratories and a network of academic partners, iOnctura is strategically positioned to develop innovative combination therapies in cancer immunology, ensuring a focused approach to tackling the complexities of cancer and fibrosis.

INBRAIN Neuroelectronics is a medical device company based in Barcelona, Spain, that specializes in developing graphene-based neural interfaces and intelligent neuromodulation systems aimed at treating brain disorders. Founded in 2019, the company offers the world's first brain-computer interface (BCI) therapeutics platform, which integrates precise BCI decoding with micrometric modulation to provide adaptive and personalized treatments for conditions such as Parkinson's disease, epilepsy, and stroke rehabilitation. Its technology enables continuous real-time monitoring and autonomous adjustments to therapy, enhancing therapeutic outcomes while reducing side effects. INBRAIN is also engaged in strategic collaborations, including with Merck KGaA, to expand its innovative solutions into peripheral nerve and systemic disease applications, thereby advancing the field of neurotechnology and bioelectronics.

Arspectra is a medical technology firm that focuses on unique augmented reality solutions for the healthcare industry.

Tensive is a biomedical startup established in 2012 to develop innovative prostheses aiming to offer a natural breast reconstruction or augmentation.Tensive is a biomedical startup established in 2012 to develop innovative prostheses aiming to offer a natural breast reconstruction or augmentation.

Herantis Pharma is a biotechnology company focused on addressing unmet clinical needs through the development of disease-modifying therapies for Parkinson's disease. The company's primary development program centers on HER-096, a peptidomimetic molecule engineered to preserve the biological activity of the neuroprotective CDNF protein. By targeting the underlying mechanisms of the disease, Herantis Pharma aims to provide innovative treatment options for patients suffering from Parkinson's disease.

NC Biomatrix is focused on developing medical therapies aimed at restoring the natural biomechanics of the spine to address low back pain. The company offers a non-invasive treatment option that involves an injectable viscous gel designed to alleviate the underlying causes of lower back pain. By targeting the biomechanics of the spine, NC Biomatrix provides a novel solution for patients suffering from osteoarthritis and related conditions, improving their quality of life through effective pain management.

Gold Standard Phantoms specializes in the development, marketing, and sale of calibration services and devices for quantitative medical imaging, particularly focusing on MRI scanners. The company provides a cloud-based data analysis platform that ensures the calibration of images is traceable to standardized values. Its innovative cylindrical phantom design addresses the need for multiple sample vials during phantom preparation, allowing clinicians, medical physicists, and radiographers to obtain reproducible quantitative measurements of diseases across different patients, scanners, and clinics. This approach not only enhances the accuracy of MRI imaging but also holds the potential to reduce medical costs over time.

Akknatek specializes in developing innovative optical testing products aimed at improving postoperative management of intraocular lenses (IOLs). The company's patented lens reviewer technology enhances patients' visual outcomes, particularly for those experiencing dislocated IOLs following cataract surgery. By providing clear protocols for treatment, the lens reviewer minimizes the risk of unexpected refractive complications and decreases the need for additional refractive procedures. This streamlined approach to postoperative monitoring not only aids clinics in managing IOL placements but also fosters greater confidence in IOL implantations, ultimately benefiting patient care and outcomes.

Herantis Pharma is a biotechnology company focused on addressing unmet clinical needs through the development of disease-modifying therapies for Parkinson's disease. The company's primary development program centers on HER-096, a peptidomimetic molecule engineered to preserve the biological activity of the neuroprotective CDNF protein. By targeting the underlying mechanisms of the disease, Herantis Pharma aims to provide innovative treatment options for patients suffering from Parkinson's disease.

CARMAT is a France-based medtech company that specializes in the development and manufacture of bioprosthetic artificial hearts aimed at treating patients with severe heart failure. Founded in 2008 and located in Vélizy-Villacoublay, the company produces biocompatible and auto-regulated total artificial hearts that closely mimic the human heart's functionality. These devices are designed for individuals experiencing chronic terminal heart failure classified as NYHA class IV or those suffering from acute terminal heart failure following a major heart attack. CARMAT's innovative solutions target patients who are not suitable for heart transplantation and have exhausted other treatment options, providing a reliable new therapeutic alternative. In addition to the artificial hearts, CARMAT also develops the associated power supply and control systems, including remote diagnosis capabilities.

INBRAIN Neuroelectronics is a medical device company based in Barcelona, Spain, that specializes in developing graphene-based neural interfaces and intelligent neuromodulation systems aimed at treating brain disorders. Founded in 2019, the company offers the world's first brain-computer interface (BCI) therapeutics platform, which integrates precise BCI decoding with micrometric modulation to provide adaptive and personalized treatments for conditions such as Parkinson's disease, epilepsy, and stroke rehabilitation. Its technology enables continuous real-time monitoring and autonomous adjustments to therapy, enhancing therapeutic outcomes while reducing side effects. INBRAIN is also engaged in strategic collaborations, including with Merck KGaA, to expand its innovative solutions into peripheral nerve and systemic disease applications, thereby advancing the field of neurotechnology and bioelectronics.

CorWave is a developer of advanced implanted cardiac support devices aimed at improving the quality of life for patients with heart failure. The company's flagship product, an innovative left ventricular assist device (LVAD), employs a unique undulating disc wave pumping mechanism. This design enhances blood flow by mimicking the natural pulsation of the heart, significantly reducing trauma to blood and minimizing complications associated with clotting and bleeding, which are common with traditional continuous flow pumps. Additionally, CorWave's LVAD is characterized by low power consumption and compact size, making it suitable for complete implantation and integration with a wireless energy transfer system. Through its pioneering technology, CorWave seeks to alleviate the burdens of heart failure and lessen the need for invasive surgical interventions.

VIVAN Therapeutics is a company focused on transforming cancer care through personalized therapeutics. It utilizes a novel assay technology licensed from the Center for Personalized Cancer Therapeutics at Mt Sinai New York, which enables the development of tailored treatment strategies. The company's approach involves the Personal Discovery Process (PDP), a unique clinical trial method designed for individual patients. This process analyzes the genetic complexity of each patient's tumor by engineering it into fruit flies, allowing for the evaluation of both FDA-approved cancer and non-cancer drugs. VIVAN Therapeutics aims to provide less toxic and more affordable treatment options by recommending combinations of these drugs, thereby enhancing the effectiveness of cancer therapies. The company is also working on new diagnostics and decision support tools to improve treatment outcomes for cancer patients.

Axiles Bionics is a Brussels based spin-off from Brubotics (VUB – Free University Brussels), striving to improve the quality of life of people with assistive robotics. Our first focus today is with amputees and bringing the next generation bionic feet to the market.

ABCDx SA is a Swiss company founded in 2014 that specializes in the development, validation, and application of biomarker tests for brain injury treatment. The company focuses on creating biomarker panels designed to identify and diagnose patients at risk for severe long-term complications resulting from conditions such as traumatic brain injuries, strokes, and post-stroke infections. The founders are prominent researchers from the University of Geneva and the Vall d’Hebron Research Institute, bringing significant expertise in biomarker discovery and clinical application. They are complemented by a third founder with extensive experience in the diagnostic and pharmaceutical industries, enhancing the company’s capacity to innovate in brain health diagnostics.

CARMAT is a France-based medtech company that specializes in the development and manufacture of bioprosthetic artificial hearts aimed at treating patients with severe heart failure. Founded in 2008 and located in Vélizy-Villacoublay, the company produces biocompatible and auto-regulated total artificial hearts that closely mimic the human heart's functionality. These devices are designed for individuals experiencing chronic terminal heart failure classified as NYHA class IV or those suffering from acute terminal heart failure following a major heart attack. CARMAT's innovative solutions target patients who are not suitable for heart transplantation and have exhausted other treatment options, providing a reliable new therapeutic alternative. In addition to the artificial hearts, CARMAT also develops the associated power supply and control systems, including remote diagnosis capabilities.

ALA Diagnostics specializes in the development and marketing of in vitro diagnostic kits aimed at addressing high-prevalence pathologies and unmet medical needs. The company focuses particularly on multiple sclerosis, offering diagnostic kits that facilitate early diagnosis of the condition. These kits are designed for seamless integration into the clinical routines of hospitals and medical centers, enabling healthcare professionals to deliver accurate results. By improving diagnostic capabilities, ALA Diagnostics aims to enhance the quality of life for individuals affected by multiple sclerosis. The company leverages collaborations with public organizations to foster innovative projects and enhance its product offerings.

Brainhero is a life science company that specializes in home-based neurofeedback therapy aimed at addressing neurological impairments, particularly Autism Spectrum Disorder (ASD) and Attention Deficit Hyperactivity Disorder (ADHD). The company offers a playful approach to brain training, allowing children to learn how to control their brain activity through the measurement of brain waves using electroencephalogram (EEG) technology. This data is visualized in a user-friendly app, facilitating an engaging experience for young users. Brainhero's services extend beyond ASD and ADHD to include other neurological issues such as intellectual disabilities, epilepsy, and anxiety. Additionally, the company provides mobile neurofeedback training that helps improve concentration and relaxation, assisting medical practitioners in early detection of neurological problems and supporting appropriate medication management for patients.

Xenikos is focused on developing innovative immunotherapy treatments aimed at addressing serious immune diseases and complications arising from transplants. The company specializes in anti-T-cell antibodies that can effectively reset the immune system. This therapeutic approach involves injecting a specific agent that targets and eliminates adult T cells, particularly those that are activated, thereby enhancing treatment outcomes for patients. By leveraging this unique mechanism, Xenikos seeks to restore health and improve the quality of life for individuals facing significant immune-related challenges.

Precisis is a medical technology company based in Heidelberg, Germany, founded in 2004. The company focuses on developing innovative medical devices aimed at treating epilepsy and enhancing patients' quality of life. Their flagship product involves a device that delivers individualized brain stimulation through a surgical procedure. This device is precisely positioned beneath the scalp over the epileptic origin in the brain, allowing for targeted therapeutic currents to be directed at specific areas without direct contact with the brain. This approach aims to provide deep and focused stimulation to effectively manage epilepsy.

Meletios Therapeutics is a biotechnology company focused on developing antiviral molecules to address both current and emerging diseases. By targeting the host mechanisms that viruses exploit, the company aims to create antiviral drugs that empower healthcare institutions to effectively treat a variety of viral infections. Through its innovative approach, Meletios Therapeutics seeks to fulfill significant medical needs in the field of infectious diseases.

Meletios Therapeutics is a biotechnology company focused on developing antiviral molecules to address both current and emerging diseases. By targeting the host mechanisms that viruses exploit, the company aims to create antiviral drugs that empower healthcare institutions to effectively treat a variety of viral infections. Through its innovative approach, Meletios Therapeutics seeks to fulfill significant medical needs in the field of infectious diseases.

Today 1 women on 8 has a breast cancer, 40% of them will have a mastectomy to cure cancer and only 14% of them will have reconstruction because actual technics does no fit for breast reconstruction. That’s why LATTICE MEDICAL develops the implantable device MATTISSE which answer to clinical and societal issues and allow women to get back their bodies and life. MATTISSE implant allows a natural reconstruction by regenerating autologous adipose tissues, custom reconstruction thanks to 3D printing and single surgery due to fully biodegradable material, which fully disappear after reconstruction. We aim in long term to replace silicon-based implant by our technology.

Ostoform is a spin-out medical device company from the University of Limerick, Ireland with a range of patented technologies, and the potential to scale, becoming a global leader in the area of ostomy skin health.

Hemispherian is a biotechnology company focused on developing innovative treatments for various types of cancer, particularly aggressive forms such as glioblastoma multiforme. The firm specializes in personalized cancer therapies and is working on a new class of small-molecule drugs designed to address significant unmet medical needs in oncology. By formulating these advanced treatments, Hemispherian aims to provide physicians with access to novel therapeutic options that can improve patient outcomes in the fight against cancer.

Hemispherian is a biotechnology company focused on developing innovative treatments for various types of cancer, particularly aggressive forms such as glioblastoma multiforme. The firm specializes in personalized cancer therapies and is working on a new class of small-molecule drugs designed to address significant unmet medical needs in oncology. By formulating these advanced treatments, Hemispherian aims to provide physicians with access to novel therapeutic options that can improve patient outcomes in the fight against cancer.

Fineheart is a France-based medical device company that specializes in innovative technologies aimed at addressing cardiovascular diseases. The company is developing an implantable cardiac device that is wirelessly powered and fully implantable, designed to provide mechanical circulatory support. This novel device optimizes cardiac output while preserving the heart's natural contractility, thereby enabling patients with heart failure to restore normal cardiac function and improve their quality of life. Fineheart's focus on advanced medical solutions positions it as a key player in the evolving landscape of cardiovascular care.

Celeris Therapeutics is an AI-driven drug discovery company focused on developing proximity-inducing compounds (PICs), particularly PIC degraders, to address diseases with significant unmet medical needs, including Parkinson's disease and various cancers. The company utilizes its proprietary Celeris One platform, which employs structure-based geometric deep learning to enhance the design and development of degraders. This platform aids in the prioritization of specific E3 ligases, the design of linkers, and the selection of the most promising compounds for synthesis. Additionally, Celeris Therapeutics operates an automated laboratory that rapidly generates experimental data for further optimization. The company collaborates with pharmaceutical and biotech firms to co-develop small-molecule degrader therapies across various therapeutic areas while also building its own drug pipeline. Celeris Therapeutics maintains offices in Menlo Park, California, and Graz, Austria.

Fineheart is a France-based medical device company that specializes in innovative technologies aimed at addressing cardiovascular diseases. The company is developing an implantable cardiac device that is wirelessly powered and fully implantable, designed to provide mechanical circulatory support. This novel device optimizes cardiac output while preserving the heart's natural contractility, thereby enabling patients with heart failure to restore normal cardiac function and improve their quality of life. Fineheart's focus on advanced medical solutions positions it as a key player in the evolving landscape of cardiovascular care.

Immunethep is a biotechnology company focused on developing innovative therapies for immune system-related diseases. Originating as a spin-off from the University of Porto, the company leverages proprietary technology to address significant unmet medical needs. Immunethep has identified a novel mechanism by which various pathogenic bacteria suppress the host immune response. By targeting this mechanism, the company aims to create broad-spectrum anti-bacterial immunotherapies. Among its initiatives, Immunethep is working on neonatal vaccines designed to protect infants from bacterial infections before birth, thereby enhancing their immunity and preventing multi-bacterial infections. Through these advancements, Immunethep strives to improve patient outcomes and contribute to the field of advanced healthcare.

Immunethep is a biotechnology company focused on developing innovative therapies for immune system-related diseases. Originating as a spin-off from the University of Porto, the company leverages proprietary technology to address significant unmet medical needs. Immunethep has identified a novel mechanism by which various pathogenic bacteria suppress the host immune response. By targeting this mechanism, the company aims to create broad-spectrum anti-bacterial immunotherapies. Among its initiatives, Immunethep is working on neonatal vaccines designed to protect infants from bacterial infections before birth, thereby enhancing their immunity and preventing multi-bacterial infections. Through these advancements, Immunethep strives to improve patient outcomes and contribute to the field of advanced healthcare.

AugmedIT B.V. is a medical software company based in Amsterdam, the Netherlands, founded in 2018. The company focuses on developing augmented and mixed reality tools that enhance surgical procedures by enabling surgeons to create holograms of patients. AugmedIT specializes in applications related to neurosurgery, medical education, and holographic visualization, as well as neuronavigation. Through its innovative technology, the company aims to improve surgical precision and training in the medical field.

Methinks is a developer of a medical imaging platform that leverages advanced artificial intelligence techniques, including Google's TensorFlow, to enhance the diagnosis of brain-related diseases, particularly acute stroke. The platform facilitates timely and universal diagnosis by using non-contrast CT imaging, which eliminates the need for contrast CT scans and significantly reduces time-to-treatment. This capability enables radiologists to effectively communicate with hospitals, stroke units, and other healthcare professionals, thereby improving the overall clinical response to stroke cases. By focusing on specific pathologies, Methinks aims to achieve clinical excellence in the diagnosis and management of neurological conditions.

IRUBIS GmbH, founded in 2017 and based in Munich, Germany, specializes in the development of mid-infrared (MIR) spectrometers and attenuated total reflection (ATR) crystals. The company focuses on enhancing Fourier transform infrared (FTIR) spectroscopy to improve the analysis of protein-based drugs. Its innovative measurement systems enable real-time bioreactor monitoring, allowing for the online assessment of glucose and lactate levels without contamination risks. IRUBIS also produces a range of ATR crystals, including single-reflection and signal-enhanced varieties, aimed at advancing industry standards for bioprocess monitoring. The company’s technology supports both upstream and downstream bioprocessing, facilitating metabolite monitoring and the detection of target proteins and contaminants through machine-learning evaluation software.

IRUBIS GmbH, founded in 2017 and based in Munich, Germany, specializes in the development of mid-infrared (MIR) spectrometers and attenuated total reflection (ATR) crystals. The company focuses on enhancing Fourier transform infrared (FTIR) spectroscopy to improve the analysis of protein-based drugs. Its innovative measurement systems enable real-time bioreactor monitoring, allowing for the online assessment of glucose and lactate levels without contamination risks. IRUBIS also produces a range of ATR crystals, including single-reflection and signal-enhanced varieties, aimed at advancing industry standards for bioprocess monitoring. The company’s technology supports both upstream and downstream bioprocessing, facilitating metabolite monitoring and the detection of target proteins and contaminants through machine-learning evaluation software.

Axiles Bionics is a Brussels based spin-off from Brubotics (VUB – Free University Brussels), striving to improve the quality of life of people with assistive robotics. Our first focus today is with amputees and bringing the next generation bionic feet to the market.

Diagnostic of preterm birth risk and induction labor success probabilities through the use of torsional ultrasound technology

Actome focuses on developing emulsion coupling technology for life science research and personalized medicine.

Kahun operates an online medical platform designed to assist healthcare organizations in improving the clinical intake process. By leveraging artificial intelligence, the platform catalogs clinical information from peer-reviewed medical literature and extracts relevant insights to facilitate informed decision-making by physicians. This approach optimizes the time doctors spend on documentation while enhancing their overall understanding of clinical knowledge. Ultimately, Kahun aims to improve clinical outcomes by providing a transparent and explainable system that supports efficient and effective diagnosis.

Restore Medical is a medical device company focused on treating congestive heart failure, specifically targeting patients with left ventricle failure. Founded in 2016 and based in Or Yehuda, Israel, the company offers ContraBand, a catheter-delivered implant designed for placement in the pulmonary arteries. This innovative device aims to enhance left ventricle ejection fraction, decrease mitral regurgitation, and restore favorable ventricular geometry. By improving patient outcomes, Restore Medical's solutions contribute to a better quality of life and aim to reduce the rates of hospital readmission among affected individuals.

Idoven is a pioneering company that has created an innovative cardiology-as-a-service platform utilizing artificial intelligence to enhance the ability of both cardiologists and non-specialist clinicians to identify, triage, and diagnose heart conditions on a large scale. The platform analyzes long-duration electrocardiograms to detect alterations in cardiac electrical activity and arrhythmias, allowing for early diagnosis and prevention of serious cardiac diseases, including myocardial infarction and sudden death. Idoven collaborates with notable partners such as AstraZeneca, Abbott, and Google, and has received investments from prominent firms like Insight Partners and Northzone. The company has been recognized with several prestigious awards for its technology, including accolades from the European Innovation Council and the Healthy Longevity Catalyst Award from the US National Academy of Medicine. Additionally, Idoven has been named one of the top 50 companies in Digital Health by CB Insights for 2023.

Onward is a medical technology company focused on developing therapies aimed at enabling functional recovery for individuals with spinal cord injuries. The company is creating an Implantable Neuro-stimulation System (INS) that features real-time motion feedback and utilizes training tools for rehabilitation. Onward has developed two platforms for neurostimulation: ARCIM, an implantable system, and ARCEX, a non-invasive transcutaneous system. To establish its customer base, Onward has targeted the United States and four European markets, namely Germany, France, the United Kingdom, and the Netherlands.

Antabio is a private biopharmaceutical company based in Labege, France, focused on developing novel treatments for drug-resistant infections, particularly targeting critical priority pathogens. Founded in 2009, the company specializes in creating antibacterial resistance-breakers that can restore the efficacy of existing antibiotics. Its key innovation includes inhibitors of bacterial metalloenzymes, specifically Metallo ß-lactamases (MBLs), which are designed to be used in combination with carbapenems to address significant treatment gaps in drug-resistant nosocomial infections. Antabio aims to provide health professionals with effective medicinal products to combat life-threatening respiratory infections, including carbapenem-resistant pneumonia and chronic pulmonary diseases. The company has received recognition for its research efforts, including a Wellcome Trust Seeding Drug Discovery Award.

Endoron Medical specializes in the development of medical devices aimed at improving the treatment of abdominal aortic aneurysms. The company focuses on creating an endovascular suture device that enhances the effectiveness of endovascular aneurysm repair procedures. By designing long-lasting sealing equipment for endografts, Endoron Medical provides healthcare professionals with advanced technology to treat patients more effectively. This innovation is intended to improve patient outcomes and streamline surgical processes in the management of abdominal aortic aneurysms.

Celeris Therapeutics is an AI-driven drug discovery company focused on developing proximity-inducing compounds (PICs), particularly PIC degraders, to address diseases with significant unmet medical needs, including Parkinson's disease and various cancers. The company utilizes its proprietary Celeris One platform, which employs structure-based geometric deep learning to enhance the design and development of degraders. This platform aids in the prioritization of specific E3 ligases, the design of linkers, and the selection of the most promising compounds for synthesis. Additionally, Celeris Therapeutics operates an automated laboratory that rapidly generates experimental data for further optimization. The company collaborates with pharmaceutical and biotech firms to co-develop small-molecule degrader therapies across various therapeutic areas while also building its own drug pipeline. Celeris Therapeutics maintains offices in Menlo Park, California, and Graz, Austria.

Elgan Pharma is a biotechnology company specializing in neonatology, dedicated to addressing medical challenges and developmental issues faced by premature infants. The company is focused on developing innovative therapies utilizing nanotechnology to prevent visual impairment, a common and multifactorial problem in preterm babies. By targeting the specific needs of this vulnerable population, Elgan Pharma aims to enhance visual outcomes and reduce the risk of significant disabilities, ultimately supporting healthcare professionals in their efforts to improve the quality of life for these infants.

Metafora Biosystems is a biotechnology company focused on developing receptor binding domains (RBDs), which are innovative ligands targeting nutrient transporters. Their technology enables the detection of subtle quantitative changes in cell physiology, reflecting metabolic variations caused by factors such as drugs, genetic mutations, cell culture conditions, and diseases. This capability positions Metafora's tools as competitive assets in various segments of the biomarker market, offering unique insights into cellular responses and enhancing understanding of metabolic processes.

Metafora Biosystems is a biotechnology company focused on developing receptor binding domains (RBDs), which are innovative ligands targeting nutrient transporters. Their technology enables the detection of subtle quantitative changes in cell physiology, reflecting metabolic variations caused by factors such as drugs, genetic mutations, cell culture conditions, and diseases. This capability positions Metafora's tools as competitive assets in various segments of the biomarker market, offering unique insights into cellular responses and enhancing understanding of metabolic processes.

S.I.T. provides copper intraoperative electron radiation therapy, flash radiation therapy research systems, a machining laboratory, a vacuum laboratory, a radio frequency laboratory, a welding laboratory, discovering, and developing services.

PoroUS combines non-ionizing 3D ultrasound technology and image guidance with sophisticated spectral signal processing to ensure the osteoporosis diagnosis. PoroUS’ cortical ultrasound back-scatter analysis offers a novel way to detect microstructural changes (porosity and thickness) in the cortical bone. PoroUS provides a precision- and operating independence-tool, which will improve the cost effectiveness and reduce the economic burden by preventing fragility fractures.

Lindhe Xtend has develops and sells user-friendly and flexible prostheses and accessories.The goal is to give amputated opportunity to live a free and moving life with high quality of life. The protests are developed in close cooperation with users under the "make it possible" draft.

AuriGen Medical Limited is an electrophysiology and structural heart company based in Dublin, Ireland, founded in 2016. The company focuses on developing innovative left atrial appendage (LAA) implants designed to address the stroke and arrhythmia risks associated with persistent atrial fibrillation (AF). AuriGen's technology targets highly symptomatic patients who are resistant to medication, a demographic that includes over 3 million individuals in the United States and Europe. The rising incidence of AF, particularly among aging populations, underscores the urgent need for effective treatment alternatives. AuriGen's devices incorporate custom LAA occluder implants and are designed to enhance patient outcomes by reducing reliance on anticoagulants and anti-arrhythmic medications. With the annual costs of managing medication-resistant AF running into billions, AuriGen aims to provide cost-effective solutions that improve treatment efficacy and patient quality of life.

GlucoSet is a medical device company focused on advancing sensor technology for glucose monitoring in intensive care units (ICUs). Elevated and unstable blood glucose levels in ICU patients can lead to serious complications, including infections, prolonged hospital stays, and increased mortality. To address this issue, GlucoSet has developed an intravascular sensor that provides continuous and precise measurements of blood glucose levels. This innovative system enhances clinicians' ability to normalize glucose levels effectively while minimizing the risk of sudden, dangerously low glucose occurrences. By improving glucose control, GlucoSet aims to reduce complications and healthcare costs associated with ICU patient care.

GlucoSet is a medical device company focused on advancing sensor technology for glucose monitoring in intensive care units (ICUs). Elevated and unstable blood glucose levels in ICU patients can lead to serious complications, including infections, prolonged hospital stays, and increased mortality. To address this issue, GlucoSet has developed an intravascular sensor that provides continuous and precise measurements of blood glucose levels. This innovative system enhances clinicians' ability to normalize glucose levels effectively while minimizing the risk of sudden, dangerously low glucose occurrences. By improving glucose control, GlucoSet aims to reduce complications and healthcare costs associated with ICU patient care.

Oivi is a company that specializes in developing an affordable AI-powered camera and platform for identifying diabetic eye diseases. Founded in 2017 and headquartered in Oslo, Norway, Oivi's technology enables retinal screening in primary care settings, helping to raise awareness and support the maintenance of eye health for individuals with diabetes. The platform features automated image capture and diagnostics, allowing for effective monitoring of eye conditions through teleconsultation. With a diverse team skilled in camera and software development, Oivi aims to facilitate early detection and prevention of diabetes-related vision loss, ultimately contributing to improved patient outcomes.